Navigation Links
Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women with Advanced Breast Cancer
Date:12/7/2011

mestane + placebo HR = 0.58 (95%CI: 0.34, 0.97) p = 0.04
  • Progression-free survival: 4.3 months for exemestane + entinostat vs. 2.3 months for exemestane + placebo HR = 0.73 (95%CI: 0.49, 1.09) p = 0.06; 1-sided significance prospectively defined as  <0.10
  • Progression-free survival of 8.5 months for exemestane + entinostat in subset of patients with increased protein acetylaton vs. 2.8 months in non acetylators HR = 0.32 (95%CI: 0.13, 0.79)
  • Trend in improved progression-free survival in hormone-resistant vs. hormone-sensitive patients
  • Exemestane combined with entinostat was well tolerated with the most frequent adverse events consisting of fatigue, gastrointestinal disturbances and hematologic abnormalities
  • "The continued survival benefit increases our confidence that entinostat will play a critical role in the treatment of women with estrogen receptor-positive metastatic breast cancer," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "We look forward to moving entinostat into phase 3 clinical testing in 2012."

    San Antonio Breast Cancer Symposium
    Presentation Date/Time: Wednesday, December 7 from 5:00 PM - 7:00 PM
    Poster Title: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study
    Session: POSTER DISCUSSION I: Endocrine Resistance
    Abstract Number: PD01-04
    Location: Ballroom A

    Breast Cancer and Hormone Therapy
    Approximately 230,000 new cases of invasive breast cancer are diagnosed in women annually in the United States and there are approximately 150,000 women living with metastatic breast cancer (MBC).  Over 70 percent of women with breast cancer have estrogen receptor-positive (ER+) breast cancer.  The most effective cancer treatments target the underlying biology and in breast canc
    '/>"/>

    SOURCE Syndax Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
    2. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
    3. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
    6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    7. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
    8. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
    9. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
    10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
    11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... 6, 2015 Increase in ... bioinformatics market in Germany through ... TechSci Research report, " Germany Bioinformatics Market Forecast & ... is projected to register a CAGR of ... witness tremendous growth on account of rising government funding ...
    (Date:7/6/2015)... MENLO PARK, Calif. , July 6, 2015 /PRNewswire/ ... of its 2015 Internal Auditing around the World ... decade, Protiviti has analyzed and reported on the evolution ... select companies from around the globe as a means ... a deeper understanding of this strategic business function. ...
    (Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/45v9b3/urinary_slings ) has ... in the US 2015-2019" report to their offering. ... in the US to grow at a CAGR of ... covers the present scenario and the growth prospects of ... period 2015-2019. To calculate the market size, the report ...
    Breaking Medicine Technology:Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 2Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 3New Edition of Internal Auditing Around the World from Protiviti Explores Changes and Trends 2United States Urinary Slings Market 2015-2019 - Vaginal Slings (TVT, TOT, and Single-incision) & Male Slings (Artificial Urinary Sphincters) 2
    (Date:7/7/2015)... ... July 07, 2015 , ... Nationally-renowned attorneys in ... new website, the Invokana Ketoacidosis Lawsuit Center . The website provides information ... resource for persons wishing to learn more about Invokana lawsuits for kidney problems, ...
    (Date:7/7/2015)... ... July 07, 2015 , ... CSG Government Solutions, ... by the Department of Vermont Health Access to provide Quality Assurance (QA) and ... and Integrated Contact Center System project. , Vermont is implementing a strategic approach ...
    (Date:7/6/2015)... Ca (PRWEB) , ... July 06, 2015 , ... Respected ... awards in 2015, marking him as an attorney who has sharp legal ... received both a Client Distinction Award for 2015 from Martindale-Hubbell and a Top 10 ...
    (Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled ... by the time they turn age 35 a quarter of all women in the U.S. will ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, who ...
    (Date:7/6/2015)... ... ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of more ... of over 3.2 percent in the years to come to hit the USD 6.9 ... an anticipated launch of a number of promising pipeline candidates and an increase in ...
    Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2
    ... Alan Mozes HealthDay Reporter , WEDNESDAY, July 20 ... shorter people to develop cancer, new British research says. ... cancer, leukemia or melanoma appears to go up about 16 ... "Taller women in our study had increased risk of ...
    ... Neurologist Michele Tagliati, MD, director of the Movement ... an elite international task force commissioned by the ... on deep brain stimulation for dystonia, an uncommon ... The resulting articles, describing the data ...
    ... , WEDNESDAY, July 20 (HealthDay News) -- In a ... Wednesday approved the blood thinner Brilinta (ticagrelor) for use ... their odds for heart attack and death. Acute ... or heart attack linked to lowered blood flow to ...
    ... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
    ... Reporter , WEDNESDAY, July 20 (HealthDay News) -- The race ... New technology promises to cut costs while speeding the amount ... and potentially provide a personalized report of health risks and ... was first mapped in 2001 and cost roughly $1 billion ...
    ... (HealthDay News) --, Liars can control certain facial expressions when ... time, a new study shows. The researchers noted the ... conducting the study, scientists randomly asked 60 people to either ... pair of movie tickets from an envelope. While being interviewed, ...
    Cached Medicine News:Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 2Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 4Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2
    ... rigid gas permeable contact lenses used for ... corrects nearsightedness (myopia). The patient wears the ... upon wakening. During the day, nearsightedness is ... and Quadra RG contact lenses apply slight ...
    ... These are rigid gas permeable contact lenses ... that temporarily corrects nearsightedness (myopia). The patient ... removes them upon wakening. During the day, ... Paragon CRT and Quadra RG contact lenses ...
    ... Aware of the High Prevalence of Sleep ... Patient Population?, , As Prevalent as Diabetes, ... (OSA), the most common form of SDB, ... the United States. Only 5% of ...
    ... ,Type 330 ,Straight, ,Konan realized an ... illumination between lenses for observation. This ... in ophthalmology and otorhinolaryngology, ,Konan offers ... can; an advanced zoom function (1:3) ...
    Medicine Products: